PT - JOURNAL ARTICLE AU - Hu, Ke AU - Zhao, Yang AU - Wang, Mengmei AU - Zeng, Qiqi AU - Wang, Xiaorui AU - Wang, Ming AU - Zheng, Zhishui AU - Li, Xiaochen AU - Zhang, Yunting AU - Wang, Tao AU - Zeng, Shaolin AU - Jiang, Yan AU - Liu, Dan AU - Yu, Wenzhen AU - Hu, Fang AU - Qin, Hongyu AU - Hao, Jingcan AU - Yuan, Jian AU - Shang, Rui AU - Jiang, Meng AU - Ding, Xi AU - Zhang, Binghong AU - Shi, Bingyin AU - Zhang, Chengsheng TI - Identification of a super-spreading chain of transmission associated with COVID-19 AID - 10.1101/2020.03.19.20026245 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.19.20026245 4099 - http://medrxiv.org/content/early/2020/03/23/2020.03.19.20026245.short 4100 - http://medrxiv.org/content/early/2020/03/23/2020.03.19.20026245.full AB - Background Super-spreading events were associated with the outbreaks of SARS and MERS, but their association with the outbreak of COVID-19 remains unknown. Here, we report a super-spreading transmission chain of SARS-CoV-2 involving an index patient, seven cancer patients, 40 health care workers and four family members.Methods We conducted a retrospective study to identify the index patient and the exposed individuals linked to a chain of transmission associated with COVID-19. We collected and analyzed the data on demographic features, exposure history, clinical presentation, laboratory investigation, radiological examination, and disease outcome of these patients.Results We identified the index patient and another presumptive “super-spreader”, who initiated and amplified a super-spreading transmission chain associated with COVID-19, respectively. There were 31 female and 21 male patients in this cohort, and the median age was 37 years (range: 22-79 years). Each of them had an exposure history with the index patient or his close contacts. Approximately 87% (45/52) of the patients had fever or other symptoms, 96% (50/52) had abnormal chest CT-scan findings, 86% of the tested patients (39/45) were positive for SARS-CoV-2 in the nasopharyngeal or throat swab specimen, 85% of the tested patients (29/34) were positive for SARS-CoV-2-specific IgM and/or IgG, 15% of the RT-PCR positive patients were tested negative for the specific IgM and/or IgG at the convalescent phase, and 15% of the RT-PCR negative patients were tested positive for the specific IgM and/or IgG. The severe patients experienced a significant decrease in oximetry saturation, lymphocyte, and platelet counts, along with a significant increase in C-reactive protein, D-dimer, and lactate dehydrogenase. All six fatal cases had comorbidities and five of the seven cancer patients (71%) died within 2-20 days of the disease onset.Conclusions The super-spreading events were associated with the outbreak of COVID-19 in Wuhan and its impact on disease transmission warrants further investigation. Cancer patients appeared highly vulnerable to COVID-19. The finding that a significant portion of SARS-CoV-2 infected patients were tested negative for the serum specific IgM and IgG at the convalescent phase should be addressed by additional studies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNo. WDRY2020-K019Funding StatementThe Hubei province key project on novel coronavirus pneumonia (2020FCA002) and the Operational Funds of the First Affiliated Hospital of Xi'an Jiaotong University.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available upon request.